Here's Why Neurocrine Biosciences Stock Rose as Much as 14.3% Today [The Motley Fool]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: The Motley Fool
The company reported second-quarter 2018 results. Maxx Chatsko ( TMFBlacknGold ) Aug 1, 2018 at 1:14PM What happened Shares of Neurocrine Biosciences ( NASDAQ:NBIX ) jumped over 14% today -- pushing the company's market cap over $10 billion for the first time -- after the company reported second-quarter 2018 results. While there were a handful of updates from the pipeline, the real news is the amazing start of the portfolio's first commercialized drug product, sold under the brand name Ingrezza. In May 2017, the drug became the first approved treatment for a condition called tardive dyskinesia, which is characterized by repetitive and involuntary movements (such as facial tics or eye blinking) and caused by long-term use of psychiatric drugs. Ingrezza generated $96.9 million in net product sales in the second quarter of 2018 and $168 million in n
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $148.00 to $158.00. They now have an "overweight" rating on the stock.MarketBeat
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $170.00 to $200.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurocrine Biosciences to Participate at Virtual Investor Conferences in MarchPR Newswire
- Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares [Yahoo! Finance]Yahoo! Finance
NBIX
Earnings
- 2/7/24 - Beat
NBIX
Sec Filings
- 3/25/24 - Form 4
- 3/21/24 - Form 144
- 3/15/24 - Form 4
- NBIX's page on the SEC website